

# Ellie J C Goldstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2895247/publications.pdf>

Version: 2024-02-01

158  
papers

14,146  
citations

44069

48  
h-index

20961

115  
g-index

162  
all docs

162  
docs citations

162  
times ranked

11670  
citing authors

#	ARTICLE	IF	CITATIONS
1	Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2014, 59, e10-e52.	5.8	1,711
2	Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections. <i>Clinical Infectious Diseases</i> , 2005, 41, 1373-1406.	5.8	1,338
3	Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2010, 50, 133-164.	5.8	1,260
4	Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2014, 59, 147-159.	5.8	1,156
5	Bacteriologic Analysis of Infected Dog and Cat Bites. <i>New England Journal of Medicine</i> , 1999, 340, 85-92.	27.0	854
6	<i>Propionibacterium acnes</i> : from Commensal to Opportunistic Biofilm-Associated Implant Pathogen. <i>Clinical Microbiology Reviews</i> , 2014, 27, 419-440.	13.6	471
7	Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Surgical Infections</i> , 2010, 11, 79-109.	1.4	401
8	Bacteriology of Moderate-to-Severe Diabetic Foot Infections and In Vitro Activity of Antimicrobial Agents. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2819-2828.	3.9	381
9	Bite Wounds and Infection. <i>Clinical Infectious Diseases</i> , 1992, 14, 633-640.	5.8	379
10	Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2018, 5, 124.	2.6	293
11	Microbiology of Animal Bite Wound Infections. <i>Clinical Microbiology Reviews</i> , 2011, 24, 231-246.	13.6	288
12	Antianaerobic Antimicrobials: Spectrum and Susceptibility Testing. <i>Clinical Microbiology Reviews</i> , 2013, 26, 526-546.	13.6	253
13	<i>Lactobacillus</i> Species: Taxonomic Complexity and Controversial Susceptibilities. <i>Clinical Infectious Diseases</i> , 2015, 60, S98-S107.	5.8	243
14	Clinical Presentation and Bacteriologic Analysis of Infected Human Bites in Patients Presenting to Emergency Departments. <i>Clinical Infectious Diseases</i> , 2003, 37, 1481-1489.	5.8	170
15	Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. <i>PLoS ONE</i> , 2018, 13, e0209205.	2.5	159
16	A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e56-e63.	9.1	150
17	Anaerobic Bacteremia. <i>Clinical Infectious Diseases</i> , 1996, 23, S97-S101.	5.8	146
18	Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data (2005-2007). <i>Clinical Infectious Diseases</i> , 2010, 50, S26-S33.	5.8	139

#	ARTICLE	IF	CITATIONS
19	Desulfovibrio desulfuricans Bacteremia and Review of Human Desulfovibrio Infections. Journal of Clinical Microbiology, 2003, 41, 2752-2754.	3.9	116
20	Animals in Healthcare Facilities: Recommendations to Minimize Potential Risks. Infection Control and Hospital Epidemiology, 2015, 36, 495-516.	1.8	105
21	In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and <i>Corynebacterium</i> spp. Antimicrobial Agents and Chemotherapy, 2004, 48, 2149-2152.	3.2	101
22	In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria. Antimicrobial Agents and Chemotherapy, 2003, 47, 1968-1971.	3.2	92
23	Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection. Antimicrobial Agents and Chemotherapy, 2011, 55, 5194-5199.	3.2	90
24	Dog bite wounds and infection: A prospective clinical study. Annals of Emergency Medicine, 1980, 9, 508-512.	0.6	89
25	Linezolid Activity Compared to Those of Selected Macrolides and Other Agents against Aerobic and Anaerobic Pathogens Isolated from Soft Tissue Bite Infections in Humans. Antimicrobial Agents and Chemotherapy, 1999, 43, 1469-1474.	3.2	88
26	Antimicrobial Activities of Fidaxomicin. Clinical Infectious Diseases, 2012, 55, S143-S148.	5.8	84
27	Comparative In Vitro Activities of Ertapenem (MK-0826) against 1,001 Anaerobes Isolated from Human Intra-Abdominal Infections. Antimicrobial Agents and Chemotherapy, 2000, 44, 2389-2394.	3.2	83
28	Biochemical Differentiation and Comparison of Desulfovibrio Species and Other Phenotypically Similar Genera. Journal of Clinical Microbiology, 2005, 43, 4041-4045.	3.9	81
29	In Vitro Activities of Daptomycin, Vancomycin, Quinupristin-Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2003, 47, 337-341.	3.2	78
30	Periodontal Bacteria in Rabbit Mandibular and Maxillary Abscesses. Journal of Clinical Microbiology, 2002, 40, 1044-1047.	3.9	77
31	Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. Journal of Antimicrobial Chemotherapy, 2004, 53, 1039-1044.	3.0	76
32	Emergence of fluoroquinolone resistance among Bacteroides species. Journal of Antimicrobial Chemotherapy, 2003, 52, 208-213.	3.0	71
33	Widespread Use of Fluoroquinolones Versus Emerging Resistance in Pneumococci. Clinical Infectious Diseases, 2002, 35, 1505-1511.	5.8	70
34	Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) Compared to Those of Erythromycin, Azithromycin, Clarithromycin, Roxithromycin, and Eight Other Antimicrobial Agents against Unusual Aerobic and Anaerobic Human and Animal Bite Pathogens Isolated from Skin and Soft Tissue Infections in Humans. Antimicrobial Agents and Chemotherapy, 1998, 42, 1127-1132.	3.2	69
35	Comparative In Vitro Activities of GAR-936 against Aerobic and Anaerobic Animal and Human Bite Wound Pathogens. Antimicrobial Agents and Chemotherapy, 2000, 44, 2747-2751.	3.2	68
36	Fluoroquinolones and Anaerobes. Clinical Infectious Diseases, 2006, 42, 1598-1607.	5.8	68

#	ARTICLE	IF	CITATIONS
37	In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2875-2879.	3.2	68
38	In Vitro Activity of Ceftobiprole against Aerobic and Anaerobic Strains Isolated from Diabetic Foot Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3959-3962.	3.2	68
39	National hospital survey of anaerobic culture and susceptibility methods: III. <i>Anaerobe</i> , 2008, 14, 68-72.	2.1	67
40	<i>Clostridium aldenense</i> sp. nov. and <i>Clostridium citroniae</i> sp. nov. Isolated from Human Clinical Infections. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2416-2422.	3.9	64
41	In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 148-155.	3.2	64
42	Comparative <i>In Vitro</i> Activities of SMT19969, a New Antimicrobial Agent, against <i>Clostridium difficile</i> and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4872-4876.	3.2	64
43	Epidemiology of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in a Network of Long-Term Acute Care Hospitals. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw856.	5.8	58
44	Comparative In Vitro Susceptibilities of 396 Unusual Anaerobic Strains to Tigecycline and Eight Other Antimicrobial Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3507-3513.	3.2	57
45	Carbapenem stewardship: does ertapenem affect <i>Pseudomonas</i> susceptibility to other carbapenems? A review of the evidence. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 11-15.	2.5	57
46	Pathway to Prevention of Nosocomial <i>Clostridium difficile</i> Infection. <i>Clinical Infectious Diseases</i> , 2015, 60, S148-S158.	5.8	55
47	Outpatient Therapy of Bite Wounds.. <i>International Journal of Dermatology</i> , 1987, 26, 123-127.	1.0	51
48	A Decade of Experience in Primary Prevention of <i>Clostridium difficile</i> Infection at a Community Hospital Using the Probiotic Combination <i>Lactobacillus acidophilus</i> CL1285, <i>Lactobacillus casei</i> LBC80R, and <i>Lactobacillus rhamnosus</i> CLR2 (Bio-K+). <i>Clinical Infectious Diseases</i> , 2015, 60, S144-S147.	5.8	51
49	Comparative <i>In Vitro</i> Activities of LFF571 against <i>Clostridium difficile</i> and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2493-2503.	3.2	50
50	Introduction of Ertapenem into a Hospital Formulary: Effect on Antimicrobial Usage and Improved In Vitro Susceptibility of <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 5122-5126.	3.2	49
51	In Vitro Activity of Gemifloxacin (SB 265805) against Anaerobes. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2231-2235.	3.2	48
52	Activities of Telithromycin (HMR 3647, RU 66647) Compared to Those of Erythromycin, Azithromycin, Clarithromycin, Roxithromycin, and Other Antimicrobial Agents against Unusual Anaerobes. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2801-2805.	3.2	47
53	Intra-Abdominal Anaerobic Infections: Bacteriology and Therapeutic Potential of Newer Antimicrobial Carbapenem, Fluoroquinolone, and Desfluoroquinolone Therapeutic Agents. <i>Clinical Infectious Diseases</i> , 2002, 35, S106-S111.	5.8	46
54	In Vitro Activities of Daptomycin, Vancomycin, and Penicillin against <i>Clostridium difficile</i> , <i>C. perfringens</i> , <i>Finogoldia magna</i> , and <i>Propionibacterium acnes</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2728-2731.	3.2	44

#	ARTICLE	IF	CITATIONS
55	Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship. <i>Clinical Infectious Diseases</i> , 2015, 60, S72-S76.	5.8	44
56	Comparative In Vitro Activities of XRP 2868, Pristinamycin, Quinupristin-Dalfopristin, Vancomycin, Daptomycin, Linezolid, Clarithromycin, Telithromycin, Clindamycin, and Ampicillin against Anaerobic Gram-Positive Species, Actinomycetes, and Lactobacilli. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 408-413.	3.2	42
57	Beyond the target pathogen: ecological effects of the hospital formulary. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, S21-S31.	3.1	42
58	In Vitro Activity of Ceftazidime-NXL104 against 396 Strains of $\beta$ -Lactamase-Producing Anaerobes. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3616-3620.	3.2	41
59	Ridinilazole: a novel therapy for Clostridium difficile infection. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 137-143.	2.5	41
60	In Vitro Activities of Doripenem and Six Comparator Drugs against 423 Aerobic and Anaerobic Bacterial Isolates from Infected Diabetic Foot Wounds. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 761-766.	3.2	40
61	Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2014-2021.	3.0	39
62	First report of Parabacteroides goldsteinii bacteraemia in a patient with complicated intra-abdominal infection. <i>Anaerobe</i> , 2010, 16, 223-225.	2.1	38
63	Necrotizing Soft Tissue Infections. <i>Infectious Disease Clinics of North America</i> , 2021, 35, 135-155.	5.1	38
64	Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 31, 363-372.	3.0	37
65	Resistance Trends in Antimicrobial Susceptibility of Anaerobic Bacteria, Part I. <i>Clinical Microbiology Newsletter</i> , 2011, 33, 1-8.	0.7	37
66	Clinical Efficacy and Correlation of Clinical Outcomes With In Vitro Susceptibility for Anaerobic Bacteria in Patients With Complicated Intra-abdominal Infections Treated With Moxifloxacin. <i>Clinical Infectious Diseases</i> , 2011, 53, 1074-1080.	5.8	36
67	Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 972-976.	3.0	35
68	In Vitro Activities of Garenoxacin (BMS 284756) against 108 Clinical Isolates of Gardnerella vaginalis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3995-3996.	3.2	33
69	Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, ii29-ii36.	3.0	33
70	In vitro activity of azithromycin and nine comparator agents against 296 strains of oral anaerobes and 31 strains of Eikenella corrodens. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 244-248.	2.5	33
71	Activities of Gemifloxacin (SB 265805, LB20304) Compared to Those of Other Oral Antimicrobial Agents against Unusual Anaerobes. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2726-2730.	3.2	32
72	Comparative In Vitro Activities of Retapamulin (SB-275833) against 141 Clinical Isolates of Propionibacterium spp., Including 117 P. acnes Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 379-381.	3.2	32

#	ARTICLE	IF	CITATIONS
73	Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program Guidelines. <i>Clinical Infectious Diseases</i> , 2016, 63, 532-538.	5.8	32
74	Evaluation of the RapID CB Plus System for Identification of <i>Corynebacterium</i> Species and Other Gram-Positive Rods. <i>Journal of Clinical Microbiology</i> , 1998, 36, 543-547.	3.9	32
75	Comparative In Vitro Activities of ABT-773 against Aerobic and Anaerobic Pathogens Isolated from Skin and Soft-Tissue Animal and Human Bite Wound Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2525-2529.	3.2	31
76	In Vitro Activity of TD-1792, a Multivalent Glycopeptide-Cephalosporin Antibiotic, against 377 Strains of Anaerobic Bacteria and 34 Strains of <i>Corynebacterium</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2194-2197.	3.2	30
77	ANAEROBIC AND AEROBIC BACTERIOLOGY OF THE SALIVA AND GINGIVA FROM 16 CAPTIVE KOMODO DRAGONS ( <i>VARANUS KOMODOENSIS</i> ): NEW IMPLICATIONS FOR THE "BACTERIA AS VENOM" MODEL. <i>Journal of Zoo and Wildlife Medicine</i> , 2013, 44, 262-272.	0.6	30
78	In Vitro Activities of the Des-Fluoro(6) Quinolone BMS-284756 against Aerobic and Anaerobic Pathogens Isolated from Skin and Soft Tissue Animal and Human Bite Wound Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 866-870.	3.2	29
79	Infection after Elective Colorectal Surgery: Bacteriological Analysis of Failures in a Randomized Trial of Cefotetan vs. Ertapenem Prophylaxis. <i>Surgical Infections</i> , 2009, 10, 111-118.	1.4	28
80	General Microbiology and In Vitro Susceptibility of Anaerobes Isolated from Complicated Skin and Soft-Tissue Infections in Patients Enrolled in a Comparative Trial of Ertapenem Versus Piperacillin-Tazobactam. <i>Clinical Infectious Diseases</i> , 2002, 35, S119-S125.	5.8	27
81	United States National Hospital Survey of Anaerobic Culture and Susceptibility Methods, II. <i>Anaerobe</i> , 1995, 1, 309-314.	2.1	26
82	Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 411-420.	3.0	26
83	Broth Microdilution and Disk Diffusion Tests for Susceptibility Testing of <i>Pasteurella</i> Species Isolated from Human Clinical Specimens. <i>Journal of Clinical Microbiology</i> , 2005, 43, 2485-2488.	3.9	26
84	Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal <i>Clostridium</i> Species: Implications for <i>Clostridium difficile</i> Recurrence. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1187-1191.	3.2	26
85	Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 347-351.	1.8	25
86	Bacterial counts from five over-the-counter probiotics: Are you getting what you paid for?. <i>Anaerobe</i> , 2014, 25, 1-4.	2.1	25
87	Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 395-401.	4.0	25
88	In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria. <i>International Journal of Antimicrobial Agents</i> , 2000, 16, 225-232.	2.5	24
89	Whole-Genome Sequencing To Identify Drivers of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Transmission within and between Regional Long-Term Acute-Care Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	24
90	In Vitro Activities of ABT-492, a New Fluoroquinolone, against 155 Aerobic and 171 Anaerobic Pathogens Isolated from Antral Sinus Puncture Specimens from Patients with Sinusitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3008-3011.	3.2	21

#	ARTICLE	IF	CITATIONS
91	Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections. <i>Infectious Diseases and Therapy</i> , 2017, 6, 149-172.	4.0	21
92	Activity of Ampicillin/Sulbactam, Ticarcillin/Clavulanate, Clarithromycin, and Eleven Other Antimicrobial Agents Against Anaerobic Bacteria Isolated from Infections in Children. <i>Clinical Infectious Diseases</i> , 1995, 20, S356-S360.	5.8	20
93	Comparative In Vitro Activities of Ertapenem (MK-0826) against 469 Less Frequently Identified Anaerobes Isolated from Human Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1136-1140.	3.2	20
94	Genetic Determinant of Intrinsic Quinolone Resistance in <i>Fusobacterium canifelinum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 434-437.	3.2	20
95	Activity of a novel carbapenem, doripenem, against anaerobic pathogens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 447-454.	1.8	20
96	In Vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of <i>Bacteroides</i> and <i>Parabacteroides</i> species. <i>Anaerobe</i> , 2018, 52, 122-124.	2.1	20
97	Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 735-741.	3.0	19
98	In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections. <i>Anaerobe</i> , 2006, 12, 63-66.	2.1	19
99	Ceftaroline versus Isolates from Animal Bite Wounds: Comparative In Vitro Activities against 243 Isolates, Including 156 <i>Pasteurella</i> Species Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6319-6323.	3.2	19
100	Comparative In Vitro Activities of Amoxicillin-Clavulanate against Aerobic and Anaerobic Bacteria Isolated from Antral Puncture Specimens from Patients with Sinusitis. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 705-707.	3.2	18
101	Molecular characterization and antimicrobial susceptibilities of extra-intestinal <i>Clostridium difficile</i> isolates. <i>Anaerobe</i> , 2007, 13, 114-120.	2.1	18
102	Re-assessment of phenotypic identifications of <i>Bacteroides putredinis</i> to <i>Alistipes</i> species using molecular methods. <i>Anaerobe</i> , 2011, 17, 130-134.	2.1	18
103	Comparative In Vitro Activities of GSK2251052, a Novel Boron-Containing Leucyl-tRNA Synthetase Inhibitor, against 916 Anaerobic Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2401-2404.	3.2	18
104	Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
105	Effect of Carbon Dioxide on Erythromycin. <i>Antimicrobial Agents and Chemotherapy</i> , 1983, 23, 325-327.	3.2	17
106	In Vitro Activities of Telithromycin and 10 Oral Agents against Aerobic and Anaerobic Pathogens Isolated from Antral Puncture Specimens from Patients with Sinusitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1963-1967.	3.2	17
107	<i>C. difficile</i> infection (CDI) in a long-term acute care facility (LTAC). <i>Anaerobe</i> , 2009, 15, 241-243.	2.1	17
108	Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw486.	3.0	17

#	ARTICLE	IF	CITATIONS
109	Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use. <i>Antibiotics</i> , 2021, 10, 408.	3.7	17
110	Patient and Microbial Genomic Factors Associated with Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Extraintestinal Colonization and Infection. <i>MSystems</i> , 2021, 6, .	3.8	16
111	Occurrence of <i>Bacteroides fragilis</i> Enterotoxin Gene-Carrying Strains in Germany and the United States. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1996-1997.	3.9	16
112	In Vitro Activities of Iodonium Salts against Oral and Dental Anaerobes. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2766-2770.	3.2	15
113	Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 546-548.	1.8	15
114	Cefoxitin in the Treatment of Aerobic and Anaerobic Infections. <i>Hospital Practice (1995)</i> , 1990, 25, 38-45.	1.0	14
115	In Vitro Activities of Garenoxacin (BMS-284756) against 170 Clinical Isolates of Nine <i>Pasteurella</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3068-3070.	3.2	14
116	Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 39-43.	2.5	14
117	Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. <i>Anaerobe</i> , 2008, 14, 8-12.	2.1	14
118	Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of <i>Clostridium difficile</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 554-556.	1.8	14
119	Comparison of the Copan eSwab System with an Agar Swab Transport System for Maintenance of Fastidious Anaerobic Bacterium Viability. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1364-1367.	3.9	14
120	Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	13
121	In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 42, 113-118.	1.8	12
122	Virulence characteristics of community-associated <i>Staphylococcus aureus</i> and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated methicillin-resistant and -susceptible <i>S. aureus</i> . <i>Journal of Medical Microbiology</i> , 2008, 57, 452-456.	1.8	12
123	Bactericidal activity of telavancin, vancomycin and metronidazole against <i>Clostridium difficile</i> . <i>Anaerobe</i> , 2010, 16, 220-222.	2.1	10
124	The underappreciated in vitro activity of tedizolid against <i>Bacteroides fragilis</i> species, including strains resistant to metronidazole and carbapenems. <i>Anaerobe</i> , 2017, 43, 1-3.	2.1	10
125	<p>Investigational Treatment Agents for Recurrent <em>Clostridioides difficile</em> Infection (rCDI)</p>. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 371-384.	3.2	10
126	In Vitro Activities of ABT-773, a New Ketolide, against Aerobic and Anaerobic Pathogens Isolated from Antral Sinus Puncture Specimens from Patients with Sinusitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2363-2367.	3.2	9



#	ARTICLE	IF	CITATIONS
127	Review of the in vitro activity and potential clinical efficacy of levofloxacin in the treatment of anaerobic infections. <i>Anaerobe</i> , 2003, 9, 75-81.	2.1	8
128	<i>In Vitro</i> Activity of Pexiganan and 10 Comparator Antimicrobials against 234 Isolates, Including 93 Pasteurella Species and 50 Anaerobic Bacterial Isolates Recovered from Animal Bite Wounds. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	8
129	<i>In Vitro</i> stability of three oral vancomycin preparations stored at 2- 5°C and ambient room temperature for up to 60 days against 100 Clostridioides (Clostridium) difficile and 51 Staphylococcus aureus strains. <i>Anaerobe</i> , 2018, 52, 83-85.	2.1	8
130	<i>In Vitro</i> Activity of Tedizolid Compared to Linezolid and Five Other Antimicrobial Agents against 332 Anaerobic Isolates, Including Bacteroides fragilis Group, Prevotella, Porphyromonas, and Veillonella Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	7
131	Resistance Trends in Antimicrobial Susceptibility of Anaerobic Bacteria, Part II. <i>Clinical Microbiology Newsletter</i> , 2011, 33, 9-15.	0.7	6
132	Activity of garenoxacin against 536 unusual anaerobes including 128 recovered from acute pelvic infections. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 131-136.	1.8	5
133	Therapy of Clostridium difficile infection: perspectives on a changing paradigm. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2375-2386.	1.8	5
134	Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 323-335.	4.1	5
135	Antimicrobial Management of Respiratory Infections in Severe Acute Respiratory Syndrome Coronavirus 2 Patients: Clinical and Antimicrobial Stewardship Programs Conundrums. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa517.	0.9	5
136	The Times They Are A-Changin'™: New Antibacterials for Skin and Skin Structure Infections. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 137-146.	6.7	4
137	Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection. <i>Pharmacotherapy</i> , 2016, 36, 1281-1289.	2.6	4
138	<i>Infections from Pets.</i> , 2017, , 656-662.e1.		4
139	Bundling Probiotics With Antimicrobial Stewardship Programs for the Prevention of Clostridioides difficile Infections in Acute Care Hospitals. <i>Infectious Diseases in Clinical Practice</i> , 2020, 28, 123-129.	0.3	4
140	Fever in a Couple Vacationing in the Mountains of Southern California. <i>Clinical Infectious Diseases</i> , 1992, 14, 1254-1258.	5.8	3
141	Serum Bactericidal Activity of Trovafloxacin Against Selected Anaerobic Pathogens. <i>Anaerobe</i> , 2001, 7, 237-240.	2.1	3
142	<i>In Vitro</i> Activities of Pexiganan and 10 Comparator Antimicrobials against 502 Anaerobic Isolates Recovered from Skin and Skin Structure Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	3
143	Bulleidia extracta Prosthetic Hip Infection After a Dental Procedure: Potential Need for Prophylaxis. <i>Clinical Infectious Diseases</i> , 2021, 73, e849-e850.	5.8	3
144	Bulleidia extracta: An underappreciated anaerobic pathogen. <i>Anaerobe</i> , 2021, 69, 102339.	2.1	3

#	ARTICLE	IF	CITATIONS
145	Animal Bites and Zoonoses: From A to Z: Alligators to Zebras. , 2015, , 659-679.		3
146	Antimicrobial Resistance of Anaerobic Bacteria. , 2008, , 207-229.		2
147	Comparative susceptibility of Gemella morbillorum to 13 antimicrobial agents. Anaerobe, 2022, 75, 102573.	2.1	2
148	Bites. , 2015, , 3510-3515.e1.		1
149	Diseases Transmitted by Cats. , 0, , 133-150.		1
150	Introduction. Journal of Antimicrobial Chemotherapy, 2004, 53, ii5-ii6.	3.0	0
151	206Implementing an Antimicrobial Stewardship Program. Open Forum Infectious Diseases, 2014, 1, S92-S92.	0.9	0
152	Animal and human bites. , 0, , 157-161.		0
153	Choosing antimicrobials for anaerobic infections. Journal of Pediatric Infectious Diseases, 2015, 04, 053-065.	0.2	0
154	Reply to Solnick. Clinical Infectious Diseases, 2015, 61, 484.2-485.	5.8	0
155	Why 2 Studies That Used the Same Probiotic May Have Come Up With Different Outcomes. Clinical Infectious Diseases, 2022, 74, 941-942.	5.8	0
156	HUMAN BITES. , 2009, , 3496-3502.		0
157	Infections from pets. , 2010, , 727-733.		0
158	Role of Asymptomatic Carriers in Long-Term Care Facility Clostridioides (Clostridium) difficile Transmission. , 2020, , 25-36.		0